ABG
JNCE

Ally Bridge Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Ally Bridge Group’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-550,000
Closed -$1.67M – 52
2022
Q2 		$1.67M Hold
550,000
– – 1.52% 22
2022
Q1 		$3.73M Sell
550,000
-25,000
-4% -$178K 2.77% 17
2021
Q4 		$4.8M Buy
+575,000
New +$4.74M 1.68% 24

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Ally Bridge Group's JNCE Position: Q3 2022 in Review

Ally Bridge Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2022, closing a stake of 550,000 shares — an estimated $1.67M sold.

Ally Bridge Group first reported a position in JNCE in Q4 2021 and held it in 3 quarters. The position peaked at $4.8M in Q4 2021. 102 funds tracked by Wall St. Rank hold JNCE as of Q3 2022.

  • Ally Bridge Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Ally Bridge Group sold 550,000 Jounce Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $1.67M.
  • Ally Bridge Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Ally Bridge Group's Jounce Therapeutics, Inc. Common Stock position peaked at $4.8M in Q4 2021.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Ally Bridge Group's 13F filing for Q3 2022, filed 14 Nov 2022.